Clinical trials: Eye Disease
Age-Related Macular Degeneration
OKKO Health Hyperacuity, Contrast and Colour Game Validation in Age-related Macular Degeneration
Smartphone apps have the potential to measure standard metrics of visual function. In addition, new tests may serve as digital biomarkers to detect early progression of disease, assess risk of developing disease or expand the…
- Trial name
- NCT05569226
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- OKKO Health
Allergic Conjunctivitis
Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.
- Trial name
- NCT00331500
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, Olopatadine Hydrochloride Ophthalmic Solution Vehicle
- Volunteers
- 287 people
- Sponsor
- Alcon Research
Retinitis Pigmentosa
Development of Visual Function Evaluation Method (2)
The objective of this study is to develop the comprehensive visual function evaluation method in severe visually impaired patient.
- Trial name
- NCT03626207
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Astellas Pharma Inc
Non-24-Hour Sleep-Wake Disorder
Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception
The purpose of this study is to evaluate the safety of tasimelteon in male and female patients who suffer from Non-24-Hour Sleep-Wake Disorder.
- Trial name
- NCT01429116
- Testing
- tasimelteon
- Where
- 22 sites in United States
- Volunteers
- 200 people
- Sponsor
- Vanda Pharmaceuticals
Usher Syndromes
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for 24 months in subjects with vision loss due to RP associated with Usher syndrome.
- Trial name
- SLO RP (NCT04355689)
- Testing
- NPI-001
- Where
- 4 sites in Australia
- Volunteers
- 49 people
- Sponsor
- Nacuity Pharmaceuticals, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension
The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine fixed combination in lowering intraocular pressure (IOP) relative to each of its individual active constituents instilled concomitantly…
- Trial name
- NCT01309204
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, Vehicle, Brinzolamide 1% ophthalmic suspension
- Volunteers
- 1,184 people
- Sponsor
- Alcon Research
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
AL-54478 Proof of Concept Study
The purpose of this study is to assess the safety and efficacy of AL-54478 0.005% compared with Latanoprost 0.005% and AL-54478 Vehicle in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01318252
- Testing
- AL-54478 0.005%, Latanoprost 0.005%, AL-54478 Vehicle
- Volunteers
- 64 people
- Sponsor
- Alcon Research
Choroideremia
A Study to Assess Choroideremia (CHM) Health Outcomes
The primary objectives of this study are to describe disease progression and severity by age in participants with CHM, to assess health-related quality-of-life, resource utilization and work productivity, and to assess…
- Trial name
- NCT04750785
- Testing
- No Intervention
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Biogen
Cataract
Multicentric Clinical Investigation to Assess Safety and Performance of Lux HighAdd IOL
The study purpose is to demonstrate safety and performance of bilateral implantation of LuxHighAdd intraocular lens compared with the LuxGood Monofocal lens.
- Trial name
- HIGHADD (NCT06446817)
- Testing
- LuxHighAdd IOL, LuxGood IOL
- Where
- 3 sites in France
- Volunteers
- 57 people
- Sponsor
- Cutting Edge SAS
Cataract, Lens Opacity
Comparison of Clinical Outcomes POD L GF vs POD F GF (PHY1707)
Prospective, randomised, controlled, single-surgeon, single-center clinical study to compare the clinical outcomes of two trifocal IOLs differing in the dominance of additional power.
- Conditions
- Cataract, Lens Opacity, Presbyopia
- Trial name
- NCT03688399
- Testing
- IOL implantation experimental, IOL implantation comparator
- Where
- Hungary
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Beaver-Visitec International, Inc.
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID). To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID.
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjogren's Syndrome
- Trial name
- NCT06417398
- Testing
- T cell injection targeting CD19 chimeric antigen receptor
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Neuromyelitis Optica Spectrum Disorder
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is a multicenter, randomized, double-blind, placebo-controlled Phase Ⅱ study to evaluate the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with different doses in participants with neuromyelitis optica…
- Trial name
- NCT05551598
- Testing
- Mitoxantrone Hydrochloride Liposome Injection
- Where
- China
- Volunteers
- 46 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Diabetic Retinopathy, DR
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic…
- Trial name
- NCT05296447
- Testing
- Standard of Care, Aflibercept
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- AbbVie
Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
The KHENEREXT Study
This is an open-label, multi-centre study in subjects with a genetically confirmed mitochondrial deoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation who completed study KH176-202.
- Conditions
- Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS)
- Trial name
- NCT04604548
- Testing
- Oral administration of 100 mg KH176 twice daily
- Where
- 4 sites in Denmark, Germany and 2 more
- Volunteers
- 11 people
- Sponsor
- Khondrion BV
Blepharitis
Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
The purpose of this study is to compare the safety and efficacy of TP-03, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles.
- Trial name
- Saturn-2 (NCT04784091)
- Testing
- TP-03, TP-03 Vehicle
- Where
- 21 sites in United States
- Volunteers
- 412 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Multiple Sclerosis, NMO Spectrum Disorder
A Study of LP-168 in Healthy Volunteers
This is a Phase I study designed to assess the safety, tolerability and pharmacokinetics of LP-168 in healthy human volunteers.
- Trial name
- NCT05432713
- Testing
- LP-168 tablet
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Myopia, Progressive
Slow Myopia Progression With Different Irradiance Light
It is a prospective clinical control study on red light control myopia with specail design spectacles for 75 children in 3 groups. Study Groups with two different powers of 0.6 mW and 1.2 mW at wavelength of 650nm.
- Trial name
- NCT05881655
- Testing
- Airdoc Red Lighting Device, Special Spectacles to Control Myopia
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Beijing Airdoc Technology Co., Ltd.
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice.
- Trial name
- NCT01853085
- Testing
- Bimatoprost Ophthalmic Solution
- Where
- Germany
- Volunteers
- 1,830 people
- Sponsor
- Allergan
Myopia
Dispensing Evaluation of a Galyfilcon A Prototype Lens and a Marketed Contact Lens
The purpose of this study is to compare visual acuity and redness of eyes between a prototype contact lens and an already marketed contact lens.
- Trial name
- NCT01180985
- Testing
- galyfilcon A prototype lens, comfilcon A
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Cataract
Laser Treatment of the Crystalline Lens
The use of a femtosecond laser in cataract surgery that gives equivalent or improved results comapred to conventional phaco-emulsification surgery.
- Trial name
- NCT01001117
- Testing
- LensAR laser surgery, Phaco-emulsification cataract surgery
- Where
- Mexico
- Volunteers
- 75 people
- Sponsor
- LensAR Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.